Outpatient Management of Bispecifics
Outpatient management of bispecific antibodies for multiple myeloma requires robust systems for patient selection, monitoring, and clear escalation pathways. Institutions must ensure that all stakeholders are well-trained and that protocols are consistently applied to mitigate potential risks.
Academic centers have developed outpatient strategies for managing bispecific antibodies, focusing on patient safety but maintained through differing points of control. We have provided varied perspectives here for your consideration.
Note: Inpatient care is always required for patients at high risk due to disease burden, previous severe toxicity, or poor performance status.
Patient Selection and Preparation
Careful patient screening to minimize risks of cytokine release syndrome (CRS) and neurotoxicity (ICANS), proximity to healthcare facilities, 24-hour caregiver support, and institutional oversight.
Dosing and Premedication
Step-up dosing schedules are standard, with Tocilizumab (an immunosuppressant) routinely used as prophylaxis. Additional pre-medications vary by protocol, including corticosteroids, acetaminophen, and antihistamines.
Monitoring and Escalation
Home monitoring, either by patient/caregiver or remote technology, is required. Initial management of fever includes self-medication and contacting medical providers. Criteria for escalation to urgent care or the emergency department (ED) depend on fever persistence, ANC count, time of day, or severity of symptoms.
I. Logistical and Eligibility Requirements
All models mandate structured preparation and stringent patient selection to mitigate the risk of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
Universal Criteria for Inpatient Administration: Regardless of the outpatient model chosen, admission is required for patients with significant disease burden, a history of severe CRS/ICANS with prior or previous doses, or a poor performance score.
| 3 different approaches that have been used by others | Approach A | Approach B | Approach C |
| Required Support | Non-emergency department (Non-ED) 24-hour care. | Patients monitored by RNs using remote monitoring wearables to report abnormal vital signs (VS). | Inpatient provider covers research calls. Patient/adult must be made aware of toxicity signs and symptoms. |
| Location/Proximity | Patient must be within 30 minutes of a hospital for 48 hours after the first target dose. | Patient must reside within a specific, defined geographic area. | Ability to immediately return to the hospital is required for any presenting signs of CRS/ICANS. |
| Caregiver Requirement | A 24-hour caregiver is required. | Caregiver required 24/7 through 48 hours after the first full dose. | Caregiver presence is required for discharge for 48 hours after first full dose. |
II. Dosing Schedules and Prophylactic Strategies
| 3 different approaches that have been used by others |
Approach A
|
Approach B
|
Approach C Under Research Protocol |
| Tocilizumab | Prophylactic Tocilizumab is administered on Day 1 as part of the schedule. | Prophylactic Tocilizumab is administered on Day 1 as part of the schedule. | Tocilizumab 8 mg/kg is administered 3 hours (+/- 1 hour) prior to Step-Up Dose #1. |
| Dexamethasone | 16 mg or 20 mg dex depending on bispecific product. | 16 mg dex. | 16 mg, 1–2 hours pre-dose. |
|
Other Premeds |
Diphenhydramine 25-50 mg (or equivalent), Acetaminophen 650 mg. | Acetaminophen 650mg and Diphenhydramine 25-50 mg | Diphenhydramine 25-50 mg, Acetaminophen 650-1000 mg. |
III. Toxicity Management and Escalation Pathways
A. Home Monitoring and Action for Fever
| Monitoring | Initial Home Action | |
|
A |
Check temperature every 8 hours while awake. |
At the first sign of fever, the patient (or caregiver) should contact the specialized attending physician. Per physician instruction, the patient may take the following home medications as needed (PRN): Recheck the patient’s temperature in 1–2 hours and call the specialized attending physician again to determine further management. |
|
B |
Measure and record body temperature at least twice daily. | |
|
C |
Remote monitoring via wearables. |
B. Management of CRS and Referral Thresholds
| Grade 1 Management and Key Threshold | Mandatory Admission/ED Referral Criteria | |
|
A |
Patient evaluated in the urgent care unit. Administer Tocilizumab 8 mg/kg IV over 1 hour. Monitor for 8 hours. | Persistent Grade 1 CRS or > Grade 2 CRS. Any presentation of ICANS. |
|
B |
If still febrile 2 hours after PRN meds: If ANC < 1000, urgent clinic during business hours or direct admit/ED after hours. If ANC < 1000, immediate report to the ED or direct admit. | Grades 2, 3, or 4 CRS. Grade 3/4 (requiring vasopressors/high-flow O2) requires mandatory 911 transport. |
|
C |
If Tocilizumab was given within 2 weeks, dexamethasone is preferred first-line treatment. Evaluation occurs at a specialized clinic during business hours. | Grade 2 or higher CRS. Grade 1 CRS that occurs on weekends, holidays, or after 5:00 PM weekdays also requires ED referral. |
C. Management of ICANS/Neurologic Toxicity
Any sign of neurologic toxicity requires immediate high-level intervention and is criterion for admission.
- Grade 1 ICANS requires taking PRN dexamethasone and reporting to the ED/direct admit.
- Grades 2, 3, or 4 requires emergency treatment and may involve/require 911 ambulance transport to the ED..